Fresenius Medical Care Ag · XETR:FME
Fresenius Medical Care — FY2020 Earnings Presentation
10 slides from Fresenius Medical Care's earnings presentation, Feb 3, 2021
Slide 1: Presentation February 3, 2021
PRESENTATION FEBRUARY 3, 2021 Rice Powell - CEO Franklin W. Maddux - CMO Helen Giza - CFO © Copyright
Slide 2: Safe harbor statement
Safe harbor statement: This presentation includes certain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Act of 1934, as amended. Forward-looking statements are inherently subject to risks and uncert
Slide 3: FY 2020 | Business Update
FY 2020 | BUSINESS UPDATE > Financial targets for 2020 achieved: > Revenue growth at mid-single digit > Net income growth slightly above top end of target range > Reported earnings in Q4 negatively impacted by macro-economic driven goodwill impairment in Latin America (approx. €195 million) > Excess
Slide 4: Assumptions | Medical Data Projections
ASSUMPTIONS | MEDICAL DATA PROJECTIONS > People with Advanced Kidney Disease are known to be highly vulnerable to COVID-19 > Access to care is essential for those patients with kidney failure that require dialysis > Modeling evidence of COVID-19 surges and risks for patients allows us to prepare pro
Slide 5: Assumptions | Medical Data Projections
ASSUMPTIONS | MEDICAL DATA PROJECTIONS > The impact of COVID-19 and mitigation strategies is worldwide and includes: > Testing for COVID-19 > Isolating patients with or suspected of the disease > Aggressive use of non-pharmaceutical interventions like masking, distancing and isolating > Utilize phar
Slide 6: FY 2021 | Early Indications
FY 2021 | EARLY INDICATIONS > Accelerating effects of excess mortality impacts treatment volumes and therewith operating leverage of > Clinic utilization and > Downstream effects on complementary assets > 2021 early indication > Revenue growth: up to mid-single digits > Net income (before potential
Slide 7: 2021 | Early Indications
2021 | EARLY INDICATIONS > Current high-level assumptions for 2021 > Monthly excess mortality to continue to accumulate for at least the first half of 2021 depending on adoption and speed of roll out of vaccinations to our worldwide patient population > COVID-19-related additional costs (e.g. PPE, p
Slide 8: 2021 | Early Indications
2021 | EARLY INDICATIONS > Close monitoring of: > Development of excess mortality in our worldwide patient population > Adoption and speed of roll out of vaccinations in patient population globally > Potential availability of government relief funding > Potential cost efficiency and restructuring me
Slide 9: Thank you!
SW” FRESENIUS Y MEDICAL CARE ) Thank you!
Slide 10: Contacts after quiet period
CONTACTS AFTER QUIET PERIOD FME INVESTOR RELATIONS Else-Kröner-Str. 1 61352 Bad Homburg v.d.H. DR. DOMINIK HEGER ROBERT ADOLPH PHILIPP GEBHARDT Germany Head of Investor Relations, Vice President Director Strategic Development & Investor Relations Investor Relations Communications | EVP TICKER: FME o
Fresenius Medical Care — FY2020 Earnings Presentation on 6ix